A Phase 4 interventional study of Azilsartan Medoxomil in Essential Hypertension and Type 2 Diabetes Mellitus, sponsored by Takeda. Completed at 12 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-03-01.
Sponsored by Takeda · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 11th largest by enrollment, is one of 2 that started in 2015, is the only one in phase 4, and was the 11th registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →
azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2015.
This study's enrollment of 380 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 837 across the 11 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Essential Hypertension by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Essential Hypertension by Takeda, this one is the 13th largest by enrollment, is one of 2 that started in 2015, is one of 2 in phase 4, and was the 15th registered.
Takeda’s Essential Hypertension studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 15 in Essential Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil (AZM) in Asian adult participants with both essential hypertension and type 2 diabetes.
The drug being tested in this study is called azilsartan medoxomil. Azilsartan medoxomil is being tested to treat people who have essential hypertension and type 2 diabetes mellitus (T2DM). This study will look at the blood pressure of people who take azilsartan medoxomil in addition to standard care for T2DM.
The study will enroll approximately 380 patients. All participants will receive azilsartan medoxomil 40 mg tablets to be administered orally, once a day, for 12 weeks. If a participant's blood pressure (BP) has not reached BP goal of \<140/85 mmHg at week 6, azilsartan medoxomil dose will be up-titrated to 80 mg daily.
All participants will be asked to take one tablet at the same time each day throughout the study.
This multi-center trial will be conducted in Asia. The overall time to participate in this study is 14 weeks. Participants will make multiple visits to the clinic, and will be contacted by 14 days after last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \<140/85 mmHg at Week 6.
Drug: Azilsartan Medoxomil
Azilsartan medoxomil tablets
Also known as: Edarbi®
Percentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 12
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Week 12
Percentage of "Treatment-Naïve" Participants Reaching BP <140/85 mmHg
Treatment-naïve participants are defined as participants who have not received anti-hypertensive treatment for at least four weeks prior to screening. At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Up to Week 12
Percentage of Participants Treated With Calcium Channel Blocker (CCB) Before Baseline Reaching BP<140/85 mmHg
At each visit three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Weeks 6 and 12
Percentage of Participants Treated With Angiotensin Converting Enzyme (ACE) Inhibitors or Other Angiotensin Receptor Blockers (ARBs) Before Baseline Reaching BP <140/85 mmHg
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Weeks 6 and 12
Percentage of Participants Treated With Thiazides Before Baseline Reaching BP <140/85 mmHg
At each visit three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Weeks 6 and 12
Percentage of "Treatment-Naïve" Participants Reaching BP <130/80 mmHg
Treatment-naïve participants are defined as participants who have not received anti-hypertensive treatment for at least four weeks prior to screening. At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Up to Week 12
Percentage of Participants Treated With CCB Before Baseline Reaching BP <130/80 mmHg
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Weeks 6 and 12
Percentage of Participants Treated With ACE Inhibitors or Other ARBs Before Baseline Reaching BP <130/80 mmHg
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Weeks 6 and 12
Percentage of Participants Treated With Thiazides Before Baseline Reaching BP <130/80 mmHg
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Weeks 6 and 12
Percentage of Participants With Systolic Blood Pressure (SBP) <140 mmHg at Week 12
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Week 12
Percentage of Participants With Diastolic Blood Pressure (DBP) <85 mmHg at Week 12
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Week 12
Percentage of Participants With DBP <90 mmHg at Week 12
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Week 12
Percentage of Participants With BP <130/80 mmHg at Week 12
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Week 12
Percentage of Participants With SBP <130 mmHg at Week 12
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Week 12
Percentage of Participants With DBP <80 mmHg at Week 12
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Week 12
Percentage of Participants With BP <140/90 mmHg at Week 12
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
Time frame: Week 12
Change From Baseline in Trough Sitting SBP at Week 12
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, baseline hypertension therapy (BHT) and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.
Time frame: Baseline and Week 12
Change From Baseline in Trough Sitting SBP at Week 12 in "Treatment-Naïve" Participants
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, baseline hypertension therapy (BHT) and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.
Time frame: Baseline and Week 12
Change From Baseline in DBP at Week 12
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, BHT and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.
Time frame: Baseline and Week 12
Change From Baseline in DBP at Week 12 in "Treatment-Naïve" Participants
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, BHT and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.
Time frame: Baseline and Week 12
Participants took part in the study at 34 investigative sites in Hong Kong, Taiwan and Thailand from 13 July 2015 to 25 November 2016.
| Milestone | Azilsartan Medoxomil (Switched) | Azilsartan Medoxomil (Add-On) | Azilsartan Medoxomil (Treatment-Naïve) |
|---|---|---|---|
| Started | 289 | 90 | 1 |
| Completed | 269 | 84 | 1 |
| Not completed | 20 | 6 | 0 |
| Withdrew: Pretreatment event/adverse event | 9 | 2 | 0 |
| Withdrew: Significant protocol deviation | 4 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Voluntary withdrawal | 2 | 2 | 0 |
| Withdrew: Investigator decision | 2 | 1 | 0 |
| Withdrew: Reason not specified | 2 | 0 | 0 |
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil (Switched) | Azilsartan Medoxomil (Add-On) |
|---|---|---|
| Percentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 12 | 59.8 (43.40 to 63.08) | 65.9 (44.07 to 75.70) |
Treatment-naïve participants are defined as participants who have not received anti-hypertensive treatment for at least four weeks prior to screening. At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil (Treatment-Naïve) |
|---|---|
| Percentage of "Treatment-Naïve" Participants Reaching BP <140/85 mmHg | 0.0 (NA to NA) |
At each visit three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil |
|---|---|
| Week 6 | 57.8 (45.36 to 71.12) |
| Week 12 | 52.3 (39.75 to 65.08) |
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil |
|---|---|
| Week 6 | 63.7 (44.83 to 68.92) |
| Week 12 | 63.7 (44.73 to 69.01) |
At each visit three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil |
|---|---|
| Week 6 | 79.3 (45.97 to 89.46) |
| Week 12 | 86.2 (43.81 to 97.18) |
Treatment-naïve participants are defined as participants who have not received anti-hypertensive treatment for at least four weeks prior to screening. At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil (Treatment-Naïve) |
|---|---|
| Percentage of "Treatment-Naïve" Participants Reaching BP <130/80 mmHg | 0.0 (NA to NA) |
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil |
|---|---|
| Week 6 | 26.6 (14.73 to 36.50) |
| Week 12 | 27.5 (15.73 to 37.10) |
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil |
|---|---|
| Week 6 | 31.1 (10.05 to 33.20) |
| Week 12 | 35.2 (12.18 to 37.37) |
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil |
|---|---|
| Week 6 | 41.4 (21.13 to 65.05) |
| Week 12 | 51.7 (29.12 to 73.67) |
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil (Switched) | Azilsartan Medoxomil (Add-On) | Azilsartan Medoxomil (Treatment-Naïve) |
|---|---|---|---|
| Percentage of Participants With Systolic Blood Pressure (SBP) <140 mmHg at Week 12 | 68.8 (57.57 to 75.78) | 70.6 (52.49 to 83.94) | 0.0 (NA to NA) |
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil (Switched) | Azilsartan Medoxomil (Add-On) | Azilsartan Medoxomil (Treatment-Naïve) |
|---|---|---|---|
| Percentage of Participants With Diastolic Blood Pressure (DBP) <85 mmHg at Week 12 | 74.6 (64.86 to 81.66) | 81.2 (67.40 to 91.05) | 0.0 (NA to NA) |
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil (Switched) | Azilsartan Medoxomil (Add-On) | Azilsartan Medoxomil (Treatment-Naïve) |
|---|---|---|---|
| Percentage of Participants With DBP <90 mmHg at Week 12 | 87.3 (85.11 to 95.34) | 87.1 (79.97 to 96.46) | 0.0 (NA to NA) |
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil (Switched) | Azilsartan Medoxomil (Add-On) | Azilsartan Medoxomil (Treatment-Naïve) |
|---|---|---|---|
| Percentage of Participants With BP <130/80 mmHg at Week 12 | 33.7 (17.01 to 37.26) | 40.0 (18.66 to 48.66) | 0.0 (NA to NA) |
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil (Switched) | Azilsartan Medoxomil (Add-On) | Azilsartan Medoxomil (Treatment-Naïve) |
|---|---|---|---|
| Percentage of Participants With SBP <130 mmHg at Week 12 | 41.3 (22.25 to 43.20) | 43.5 (20.17 to 50.31) | 0.0 (NA to NA) |
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil (Switched) | Azilsartan Medoxomil (Add-On) | Azilsartan Medoxomil (Treatment-Naïve) |
|---|---|---|---|
| Percentage of Participants With DBP <80 mmHg at Week 12 | 57.6 (36.82 to 59.95) | 65.9 (41.33 to 75.07) | 0.0 (NA to NA) |
Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.
| percentage of participants | Azilsartan Medoxomil (Switched) | Azilsartan Medoxomil (Add-On) | Azilsartan Medoxomil (Treatment-Naïve) |
|---|---|---|---|
| Percentage of Participants With BP <140/90 mmHg at Week 12 | 65.9 (52.51 to 71.04) | 68.2 (48.42 to 79.92) | 0.0 (NA to NA) |
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, baseline hypertension therapy (BHT) and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.
| mmHg | Azilsartan Medoxomil (Switched) | Azilsartan Medoxomil (Add-On) |
|---|---|---|
| Change From Baseline in Trough Sitting SBP at Week 12 | -14.1 ± 1.39 | -13.3 ± 2.12 |
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, baseline hypertension therapy (BHT) and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.
| mmHg | Azilsartan Medoxomil (Treatment-Naïve) |
|---|---|
| Change From Baseline in Trough Sitting SBP at Week 12 in "Treatment-Naïve" Participants | -7 ± NA |
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, BHT and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.
| mmHg | Azilsartan Medoxomil (Switched) | Azilsartan Medoxomil (Add-On) |
|---|---|---|
| Change From Baseline in DBP at Week 12 | -4.9 ± 0.76 | -5.7 ± 1.16 |
At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, BHT and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.
| mmHg | Azilsartan Medoxomil (Treatment-Naïve) |
|---|---|
| Change From Baseline in DBP at Week 12 in "Treatment-Naïve" Participants | 20 ± NA |
Collected over From first dose of study drug up to 14 days after the date of the last dose of study drug (up to 14 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Before Week 6 Azilsartan Medoxomil 40 mg | — | 4/380 (1.1%) | 0/380 (0%) |
| After Week 6 Azilsartan Medoxomil 40 mg | — | 3/258 (1.2%) | 0/258 (0%) |
| After Week 6 Azilsartan Medoxomil 80 mg | — | 1/97 (1%) | 0/97 (0%) |
| Event | Before Week 6 Azilsartan Medoxomil 40 mg | After Week 6 Azilsartan Medoxomil 40 mg | After Week 6 Azilsartan Medoxomil 80 mg |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/380 | 0/258 | 1/97 |
| SepsisInfections and infestations | 0/380 | 0/258 | 1/97 |
| Acute kidney injuryRenal and urinary disorders | 1/380 | 1/258 | 1/97 |
| Acute myocardial infarctionCardiac disorders | 0/380 | 1/258 | 0/97 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/380 | 1/258 | 0/97 |
| Cardiac failureCardiac disorders | 1/380 | 0/258 | 0/97 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/380 | 0/258 | 0/97 |
| HypotensionVascular disorders | 1/380 | 0/258 | 0/97 |
Safety analysis set included all participants who took at least 1 dose of azilsartan medoxomil.
| Age, Continuous(years) | Azilsartan Medoxomil |
|---|---|
| Mean | 61.6 ± 9.77 |
| Age, Customized(Participants) | Azilsartan Medoxomil |
|---|---|
| < 65 years old | 221 |
| >=65 to <75 years old | 159 |
| Sex: Female, Male(Participants) | Azilsartan Medoxomil |
|---|---|
| Female | 197 |
| Male | 183 |
| Race/Ethnicity, Customized(Participants) | Azilsartan Medoxomil |
|---|---|
| Asian | 380 |
| Region of Enrollment(Participants) | Azilsartan Medoxomil |
|---|---|
| Taiwan, Province Of China | 139 |
| Thailand | 219 |
| Hong Kong | 22 |
| Height(cm) | Azilsartan Medoxomil |
|---|---|
| Mean | 161.1 ± 9.57 |
| Weight(kg) | Azilsartan Medoxomil |
|---|---|
| Mean | 72.04 ± 15.072 |
| Body Mass Index (BMI)(kg/m^2) | Azilsartan Medoxomil |
|---|---|
| Mean | 27.64 ± 4.354 |
3 further baseline measures are reported on the registry.
Ran from Jul 2015 to primary completion in Nov 2016, 16 months.
Results were first posted in Mar 2019, 2 years 3 months after primary completion.
Of 22 phase 4 interventional studies under Essential Hypertension, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 36. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azilsartan medoxomil